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1. Background {#ehf212610-sec-0004}
=============

Heart failure (HF) strongly affects quality of life and physical performance.[1](#ehf212610-bib-0001){ref-type="ref"}, [2](#ehf212610-bib-0002){ref-type="ref"} Treatment with sacubitril/valsartan is associated with reduction in mortality and HF admission paralleled by improved quality of life and tolerance to exercise.[3](#ehf212610-bib-0003){ref-type="ref"}, [4](#ehf212610-bib-0004){ref-type="ref"} Frailty is a common condition in HF patients with unfavourable effects on the course of disease,[5](#ehf212610-bib-0005){ref-type="ref"}, [6](#ehf212610-bib-0006){ref-type="ref"}, [7](#ehf212610-bib-0007){ref-type="ref"} especially for those patients where physical frailty (PF) is predominant.[8](#ehf212610-bib-0008){ref-type="ref"}, [9](#ehf212610-bib-0009){ref-type="ref"} Moreover, frailty provides a risk stratification in patients undergoing cardiac surgical interventions or heart transplantation (HT)[10](#ehf212610-bib-0010){ref-type="ref"} and in patients with advanced HF undergoing surgical intervention with bridge to ventricular assist device.[11](#ehf212610-bib-0011){ref-type="ref"}

1.1. Aim {#ehf212610-sec-0005}
--------

The aim of this study was to evaluate the midterm effects (2 years\' follow‐up) on functional parameters, including PF, of sacubitril/valsartan in advanced HF patients listed for HT.

2. Methods {#ehf212610-sec-0006}
==========

Between November 2016 and November 2018, we enrolled 45 consecutive patients with advanced HF in non‐urgent waiting list for HT. Patients were required to have ejection fraction (EF) of ≤35% and to be taking a stable dose of a beta‐blocker and an angiotensin‐converting enzyme inhibitor (ACEI) or angiotensin receptor blockers (ARBs) for at least 4 weeks before enrolment. Angiotensin‐receptor neprilysin inhibitor was started 36 h after discontinuation of ACEI/ARB therapy. Two patients with systolic blood pressure (BP) \< 90 mmHg and one patient with EF \> 35 did not initiate treatment. Thus, 42 patients attended the first follow‐up evaluation after 2 weeks of treatment, and then a monthly appointment was scheduled. The dosage of sacubitril/valsartan was increased if tolerance was good. All patients initiated with the dosage of 24/26 bis in die (b.i.d.).

2.1. Frailty {#ehf212610-sec-0007}
------------

Frailty was considered as primary endpoint of the study and was assessed using an adapted version of Fried\'s frailty phenotype[9](#ehf212610-bib-0009){ref-type="ref"} in a modified version previously used in advanced HF patients in waiting list for HT.[10](#ehf212610-bib-0010){ref-type="ref"} The five functional domains assessed were exhaustion, slowness, weakness, physical inactivity, and loss of appetite. Appetite was assessed by asking: 'Have you, in the last three months, been eating more/less than usual?' A response of 'less' was classified as poor appetite.[10](#ehf212610-bib-0010){ref-type="ref"}

2.2. Cardiovascular evaluation {#ehf212610-sec-0008}
------------------------------

All patients were evaluated by means of echocardiogram, right heart catheterization, cardiopulmonary exercise test, 6 min walk test (6MWT), and N‐terminal pro‐brain natriuretic peptide (NT‐pro‐BNP) (considered as secondary endpoints). Drug consumption, creatinine, blood urea nitrogen, sodium, and potassium were assessed at the beginning of the treatment and monthly during the treatment.

2.3. Statistical analysis {#ehf212610-sec-0009}
-------------------------

Variables are reported as means with standard deviations. Categorical variables are expressed as number (percentages). The only variable not normally distributed was pro‐BNP presented as median and inter‐quartile range. We analysed before‐treatment and after‐treatment differences using paired Student\'s *t*‐test for continuous variables and Fisher\'s exact test to compare categorical values. One‐way repeated‐measures ANOVA was used for normally distributed data to evaluate differences in 6MWT, systolic pulmonary artery pressure (PAPs), and PF at baseline, 1 month, 6 months, 12 months, and end of follow‐up; and post‐hoc Bonferroni analysis was used to evaluate differences between measures among different time points. Kruskal--Wallis test was performed for non‐parametric data as NT‐pro‐BNP.

3. Results {#ehf212610-sec-0010}
==========

Of the 42 patients in waiting list for HT enrolled, five patients (12.5%) discontinued therapy owing to intolerable side effects, leading the final sample to 37 patients. All patients had an implantable cardioverter defibrillator, 45.9% of patients had a cardiac resynchronization therapy, and 18.9% of patients have been previously treated with MitraClip for severe mitral regurgitation. All patients were on treatment with beta‐blockers, ACEIs, or ARBs and furosemide; 62.2% with mineralocorticoid antagonist; 5.7% with metolazone; 18.9% with digitalis; and 21.6% with ivabradine (*Table* [*S1*](#ehf212610-supitem-0001){ref-type="supplementary-material"}). After 3 months of treatment with sacubitril/valsartan, 40.5% of patients received the target dose of 97/103 mg b.i.d., 43.2% the half dose (49/51 mg b.i.d.), and 16.2% the low dose (24/26 mg b.i.d.). Dosage of beta‐blockers, ivabradine and digoxin remained stable during the follow‐up, furosemide decreased, and mineralocorticoid agonist was used by 73.0% instead of 62.2% at baseline. After a mean follow‐up of 17.1 ± 4.4 months (minimum 10 and maximum 24 months), there were no deaths, and two patients were suspended from waiting list because of age (70 and 67 years old) in stable clinical condition. Seven patients were underwent transplantation, and treatment was discontinued. Two patients were treated with mechanical support, one total artificial heart and one left ventricular assist device (LVAD), because of worsening of clinical status. At baseline, 64.9% were in New York Heart Association (NYHA) III and 35.1% NYHA IIIB. At the end of follow‐up, NYHA class improved significantly (3.1 ± 0.4 at baseline vs. 2.4 ± 0.6 at the end of follow‐up; *P* = 0.002), specifically 56.8% in NYHA II, 40.5% in NYHA III, and 2.7% in NYHA III B (*P* \< 0.001). PF decreased from 3.35 ± 1.0 at baseline to 1.57 ± 1.3 at the end of follow‐up (*P* \< 0.001) with a significant reduction in all domain of PF (*Table* [1](#ehf212610-tbl-0001){ref-type="table"}). At the end of follow‐up, 32.4% had a frailty score ≥ 3 with respect to 78.4% at baseline (*P* \< 0.001). VO~2~ max consumption and 6MWT increased, while pulmonary systolic BP, *E*/*E*′, VE/VCO~2~ slope, and NT‐pro‐BNP decreased. Both diastolic and systolic BP decreased, but only diastolic BP was statistically significant. No differences were observed during follow‐up for left ventricular EF, tricuspid annular plane systolic excursion, and inferior vena cava, while a significant reduction in mitral regurgitation was found in 28 patients free of MitraClip (*Table* [2](#ehf212610-tbl-0002){ref-type="table"}). Moreover, a significant decrease in furosemide dosage was observed (102.7 ± 69.4 mg to 78.7 ± 66.3 mg; *P* = 0.040), while no differences were observed in mineralocorticoid antagonist and metolazone (*Table 2*). A significant reduction in pulmonary artery systolic and mean pressure was observed; pulmonary capillary wedge pressure measured by right heart catheterization at baseline and after 1 year of follow‐up was observed. No statistically significant differences were found in right atrial pressure, diastolic pressure, cardiac index, cardiac output, and pulmonary vascular resistance (*Table* [3](#ehf212610-tbl-0003){ref-type="table"}). These improvements occurred starting at the first month of treatment and were persistent during follow‐up. The mean scores for NT‐pro‐BNP (*Figure* [*1*](#ehf212610-fig-0001){ref-type="fig"} *A*), PAPs (*Figure* [*1*](#ehf212610-fig-0001){ref-type="fig"} *B*), 6MWT (*Figure* [*1*](#ehf212610-fig-0001){ref-type="fig"} *C*), and PF (*Figure* [*1*](#ehf212610-fig-0001){ref-type="fig"} *D*) statistically significantly different between each time point. Post‐hoc tests revealed that sacubitril/valsartan elicited a considerable reduction in NT‐pro‐BNP concentration from pretreatment progressively to the end of follow‐up (2557.9 ± 3413.0 pg/mL) (*P* = 0.008) (*Figure 1A*). A reduction statistically significant was also observed for PAPs after 1 month of treatment and remained stable during the follow‐up (*Figure* [*1*](#ehf212610-fig-0001){ref-type="fig"} *B*). Similarly, 6MWT increased from pretreatment to the end of follow‐up (*Figure* [*1*](#ehf212610-fig-0001){ref-type="fig"} *C*), while PF reduced from pretreatment to 1 month (*P* \< 0.000) and remained stable during the follow‐up (*Figure* [*1*](#ehf212610-fig-0001){ref-type="fig"} *D*). Moreover, when we analysed differences between the 15 patients who reached target dose of 400 mg vs. the 22 patients who reached 200 mg, we do not find any statistical differences in 6MWT, VO~2~ max, NYHA, NT‐pro‐BNP, and PAPs measured at entry and after 1 year of follow‐up.

###### 

Comparison of physical frailty domain before and after the start of sacubitril/valsartan

  Physical frailty          Pre          Post      *P* value
  --------------------- ------------ ------------ -----------
  All                    3.95 ± 0.8   1.59 ± 1.3     0.000
  Exhaustion                94.3         37.1        0.000
  Slowness                  85.7         22.9        0.000
  Weakness                  88.6         31.4        0.000
  Physical inactivity       91.4         62.9        0.003
  Loss of appetite          28.6          0          0.001

###### 

Comparison of the analytical and clinical characteristics before and after the start of sacubitril/valsartan

  Clinical features of heart failure             Pre \#37          Post \#37      *P* value
  ------------------------------------------ ----------------- ----------------- -----------
  NYHA class                                     3.1 ± 0.4         2.4 ± 0.6        0.000
  NYHA class II (%)                                  0               56.8           0.000
  NYHA class III (%)                               64.9              40.5            ---
  NYHA class III B (%)                             35.1               2.7            ---
  Left ventricular ejection fraction (%)        23.5 ± 5.8        24.4 ± 6.3        0.299
  *E*/*E*′                                      15.4 ± 5.2        13.6 ± 5.1        0.044
  TAPSE                                         16.5 ± 4.6        16.3 ± 3.7        0.862
  Pulmonary systolic blood pressure (mmHg)      49.4 ± 14.8       42.3 ± 12.3       0.013
  IVC (mm)                                      19.3 ± 4.2        18.1 ± 4.0        0.167
  Mitral regurgitation---absent (%)                25.0              32.1           0.003
  Mitral regurgitation---mild (%)                  46.4              42.9            ---
  Mitral regurgitation---moderate (%)              21.4              17.9            ---
  Mitral regurgitation---severe (%)                 7.1               7.1            ---
  6 min walk test (m)                          229.2 ± 103.2     367.5 ± 102.5      0.000
  VO~2~ max (mL/kg/min)                         10.3 ± 2.3        11.9 ± 2.6        0.000
  VE/VCO~2~ (slope)                             38.0 ± 10.8       34.5 ± 6.8        0.003
  Systolic blood pressure (mmHg)               110.0 ± 11.5      104.3 ± 17.1       0.056
  Diastolic blood pressure (mmHg)               73.1 ± 8.1        66.4 ± 10.8       0.002
  Heart rate (b.p.m.)                           71.3 ± 15.5       69.8 ± 11.4       0.426
  Creatinine (mg/dL)                             1.3 ± 0.4         1.3 ± 0.4        0.428
  BUN (mg/dL)                                   70.4 ± 50.4       61.7 ± 30.1       0.177
  Na (mEq/L)                                    139.0 ± 2.4       139.9 ± 2.4       0.083
  K (mEq/L)                                      4.5 ± 0.5         4.6 ± 0.5        0.410
  NT‐pro‐BNP (pg/mL)                          4943.0 ± 5326.8   2257.9 ± 3413.1     0.000
  HbA1c (%)                                      6.3 ± 1.0         6.2 ± 0.8        0.083
  Treatment                                                                      
  Furosemide (mg b.i.d.)                       102.7 ± 69.4       78.7 ± 66.3       0.040
  Mineralocorticoid agonist (mg b.i.d.)         36.8 ± 38.7       46.0 ± 37.0       0.136

BUN, blood urea nitrogen; HbA1c, glycated haemoglobin; IVC, inferior vena cava; NT‐pro‐BNP, N‐terminal pro <https://www.sciencedirect.com/topics/medicine-and-dentistry/brain-natriuretic-peptide>; NYHA, New York Heart Association; TAPSE, tricuspid annular plane systolic excursion; VE/VCO~2~, ventilation/carbon dioxide production; VO~2~ max, peak oxygen consumption.

###### 

Comparison of right heart catheterization parameters before and after the start of sacubitril/valsartan

  Right heart catheterization                       Pre           Post           *P* value
  ------------------------------------------------- ------------- ------------- -----------
  Right atrial pressure (mmHg)                      11.2 ± 3.4    9.5 ± 2.4        0.062
  Pulmonary artery pressure systolic (mmHg)         45.3 ± 12.3   40.6 ± 11.1      0.002
  Pulmonary artery pressure diastolic (mmHg)        24.4 ± 7.1    22.2 ± 7.6       0.071
  Pulmonary artery pressure mean (mmHg)             32.9 ± 9.9    29.7 ± 9.5       0.000
  Pulmonary capillary wedge pressure (mmHg)         24.9 ± 9.5    23.4 ± 8.3       0.039
  Pulmonary vascular resistance (Wood units/m^2^)   3.6 ± 2.0     3.5 ± 1.4        0.702
  Cardiac output                                    4.7 ± 0.8     4.6 ± 0.9        0.556
  Cardiac index                                     2.4 ± 0.5     2.3 ± 0.6        0.305

![Mean scores for N‐terminal pro‐brain natriuretic peptide (NT‐pro‐BNP) (A), pulmonary blood pressure (mmHg) \[systolic pulmonary artery pressure (PAPs)\] (B), 6 min walk test (6MWT) (C), and physical frailty (PF) (D), in each time point (baseline, 1 month, 6 months, 12 months, and end of follow‐up). Post‐hoc tests revealed that sacubitril/valsartan elicited a considerable reduction in NT‐pro‐BNP concentration, PAPs, 6MWT, and PF from pretreatment to the end of follow‐up (\**P* \< 0.01).](EHF2-7-757-g001){#ehf212610-fig-0001}

4. Discussion {#ehf212610-sec-0011}
=============

Our study demonstrates an improvement of PF in patients with advanced HF on waiting list for HT treated with sacubitril/valsartan. PF improvement was similar to that observed for 6MWT and for haemodynamic parameters, that is, NT‐pro‐BNP and PAPs. These changes appeared early already in the first visit at 1 month and maintained over 2 years of follow‐up.

In the present study, the main effect of sacubitril/valsartan is the improvement of functional performance including PF together with 6MWT and VO~2~ max and a reduction in PAPs, *E*/*E*′, VE/VCO~2~ slope, and NT‐pro‐BNP. At the same time, right heart catheterization demonstrated a decrease in pulmonary artery mean and systolic pressure and pulmonary capillary wedge pressure. In addition, mitral regurgitation decreased in the patients free of MitraClip.[12](#ehf212610-bib-0012){ref-type="ref"} Previous studies have demonstrated a strong impact of frailty on outcomes such as institutionalization and mortality.[5](#ehf212610-bib-0005){ref-type="ref"}, [6](#ehf212610-bib-0006){ref-type="ref"}, [7](#ehf212610-bib-0007){ref-type="ref"}, [8](#ehf212610-bib-0008){ref-type="ref"}, [9](#ehf212610-bib-0009){ref-type="ref"}, [10](#ehf212610-bib-0010){ref-type="ref"}, [11](#ehf212610-bib-0011){ref-type="ref"} Even frailty is considered a typical geriatric syndrome[5](#ehf212610-bib-0005){ref-type="ref"}, [6](#ehf212610-bib-0006){ref-type="ref"}; in the last decade, it is used to identify the advanced phase of chronic disease such as HF.[13](#ehf212610-bib-0013){ref-type="ref"} PF is one of the domains frequently used to assess the severity of disease in order to decide the possible medical treatment (transcatheter aortic valve implantation, LVAD, and HT).[10](#ehf212610-bib-0010){ref-type="ref"}, [11](#ehf212610-bib-0011){ref-type="ref"} In advanced stages of HF, a loss of skeletal muscle mass (sarcopenia) is commonly observed, and this contributes to reduced exercise capacity and frailty.[14](#ehf212610-bib-0014){ref-type="ref"}, [15](#ehf212610-bib-0015){ref-type="ref"}

4.1. Limitation of the study {#ehf212610-sec-0012}
----------------------------

We acknowledge that this is a small single‐centre study lacking of control group. However, the overwhelming benefit demonstrated by sacubitril/valsartan in Paradigm‐HF trial[3](#ehf212610-bib-0003){ref-type="ref"} rendered non‐ethical the decision to limit this important treatment in a second arm of the study not receiving the drug.

5. Conclusions {#ehf212610-sec-0013}
==============

Our data established that sacubitril/valsartan could improve PF in patients with advanced HF in waiting list for HT. The relevance of this treatment is due to the rapid and persistent effect of the treatment in the midterm.
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**Table S1.** Baseline characteristics of patients prior to the start of co‐treatment with sacubitril/valsartan.

###### 

Click here for additional data file.
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